Combined effects of female hormones and exercise on hypoxic ventilatory response.
Mild elevations in metabolic rate may influence hypoxic ventilatory response (HVR) differently in men and women. The possible involvement of the female hormones in accounting for this gender difference is supported by observations that mild exercise raised HVR in ovariectomized women treated with estrogen and progestin but not in the same women treated with placebo (Regensteiner et al., 1989). We compared the effects of mild exercise on HVR in 12 women in the follicular phase vs the luteal phase of the menstrual cycle and during MPA (medroxyprogesterone acetate, 20 mg tid) vs placebo treatment. End-tidal PCO2 fell in the luteal compared to the follicular phase and in the follicular MPA compared to the follicular placebo condition. Resting HVR was similar in subjects in the follicular versus the luteal phases of the menstrual cycle and in MPA-treated vs placebo-treated subjects at either the existing (eucapnia) or follicular placebo (normocapnia) end-tidal PCO2. Mild exercise increased expired ventilation but not HVR in placebo-treated subjects in the follicular or luteal placebo conditions. In MPA-treated subjects, exercise raised HVR in the luteal phase (P less than 0.05) and tended to increase HVR in the follicular phase (P = 0.08). The increase in HVR with exercise was greater in MPA-treated subjects than in women given placebo (delta rest to exercise = 26% vs 9%, P less than 0.05). We concluded that elevations in progestin levels achieved by administering progestin in the luteal phase of the menstrual cycle potentiated the effect of metabolic rate on HVR.
Regensteiner
J G
JG
Cardiovascular Pulmonary Research Laboratory, University of Colorado Health Sciences Center, Denver.
McCullough
R G
RG
McCullough
R E
RE
Pickett
C K
CK
Moore
L G
LG
D000328:Adult; D015444:Exercise / Q000502:physiology; D005260:Female; D005498:Follicular Phase / Q000502:physiology; D012739:Gonadal Steroid Hormones / Q000502:physiology*; D006801:Humans; D000860:Hypoxia / Q000503:physiopathology*; D008183:Luteal Phase / Q000502:physiology; D008525:Medroxyprogesterone / Q000031:analogs & derivatives / Q000494:pharmacology; D017258:Medroxyprogesterone Acetate; D008660:Metabolism; D012119:Respiration / Q000187:drug effects / Q000502:physiology*
D012739:Gonadal Steroid Hormones; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone